Celldex Presents Data Supporting Glembatumumab Vedotin, CD40 Program

(RTTNews) - Celldex Therapeutics, Inc. (CLDX) Wednesday said it will present data supporting the clinical development of glembatumumab vedotin and the preclinical CD40 Program at the annual meeting of American Association for Cancer Research in New Orleans.

The presentations include data on the understanding of glembatumumab vedotin's mechanism of action and further validation of the overexpression of its target, gpNMB or glycoprotein NMB, in a wide range of tumor types.

In a poster presentation, the company will depict the development and characterization of CD40 antibody agonists for cancer immunotherapy. CD40 is a key activator of immune responses.

Additionally, the company said the drug candidates were shown to upregulate CD95/Fas, a receptor involved in apoptosis, on B cell lymphoma cell lines and to mediate potent anti-tumor activity against the lymphomas in vivo.